GBI Research, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth" Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas.
Click for report details: http://www.radiantinsights.com/research/melanoma-therapeutics-market-to-2020-rising-prevalence-and-evolving-treatment-algorithms-to-drive-market-growth
Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.
Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected...